



Screening for T1D and Celiac Disease: The US Perspective

Edwin Liu, MD Colorado Center for Celiac Disease

Disclosures

- Takeda: Advisory board
- UpToDate celiac disease chapter

*These activities are not related to any of the data we will be presenting today

JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT Screening for Celiac Disease US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

- In 2017, USPSTF found **inadequate evidence** on the harms of screening for or treatment of celiac disease.
- Concluding that the **current evidence is insufficient** to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons.

Current recommendations on screening for CD

- No GI group at present recommends screening of the general population
- Screening can be targeted based on:
 - Concerning symptoms
 - Higher risk group

Recommendations fail to recognize that most CD cases are asymptomatic or subclinical, and most do not have a known risk factor.

American College of Gastroenterology 2023 ESPGHAN 2020, 2022 AGA 2019 World Gastroenterology Organization 2017 NASPGHAN 2004, 2016 National Institute for Health and Care Excellence (NICE) 2015

Why mass screening?

- Fits most of the WHO criteria and most cases remain undiagnosed:
 - Common
 - Testing is simple
 - Culturally acceptable
 - There is a treatment
 - Clinical detection is difficult without screening
 - We lack data on whether nontreatment can lead to severe long-term health complications
 - We lack sufficient data on cost effectiveness

The data to support mass screening for CD is growing

- Health outcomes:
 - Individuals with screening-identified CD may have a similar disease severity to clinically-identified CD
 - There are overall health benefits in treating screening-identified CD with the GFD
- Quality of life:
 - QOL in screened patients is not different from controls or even lower
- GFD had a positive impact on:
 - Health and psychological well being
 - No decrease in QOL, or improved QOL

US data is sparse but available data consistent with prior findings in Europe with regards to improved health, QoL and adherence – ASK study Stahl et al. Clin Gastroenterol Hepatol 2024


fective, especially in children data yet)

Mass screening for childhood celiac disease and diabetes PI: Marian Rewers




ASK is a *free* population screening initiative for early type 1 diabetes and celiac disease
Find early signs of diabetes or celiac in children—before they get very sick
Assess the feasibility of universal screening
Increase public awareness of type 1 diabetes and CD

Pathway Based on TGA testing




Celiac Center Follow Up



ASK: the first 10,000 screened

51.6% Hispanic (vs 21.7% in Colorado)
Of all TGA⁺ cases, 90% did not have a family history of celiac disease or T1D

Symptoms not a predictor of TGA⁺
 •30% TGA positive have symptoms
 •30% TGA negative have symptoms



Stahl M et al, Am J Gastroenterol 2021

Projected TGA⁺ prevalence of 1.9%

Attitudes and behaviors surrounding CD screening

Families who came to see GI were:

- Generally amenable to endoscopy
- Don't like the long wait times to see GI
- Amenable to GFD if CD is diagnosed with or without symptoms

We are learning about the barriers to follow-up care - not all saw GI

- There was a tendency for some families to accept a CD diagnosis without further testing or endoscopy
- Some did not follow-up because their PCP discouraged it
- Some declined follow-up because their child was asymptomatic
- The problem of access to a provider in a timely fashion

From the biased GI perspective:

With a positive test, a CLINICAL referral to GI for further management is appropriate. Importance of integration of the screening process into the system

- tests results readily visible by providers
- test results familiar to providers
- able to place referrals directly to GI

In the US, the CD lags behind T1D in terms of readiness for mass screening

- Growing US data on benefits and potential harms of CD screening, but still lack cost data
 - At what point is the data enough?
- We need to better understand general public and provider attitudes about mass screening
 - If they don't buy into it, they aren't going to do it (regardless of the data)
- Screening is just half the battle the other half is knowing what to do with a positive test
 - We're responsible for them, how do we get them in to be seen?

Can screening for both diseases help us advance mass screening?



- Shared screening costs
- Could result in increased public awareness
- Could increase screening acceptance

Priorities and challenges

- Best practices for managing a positive screening test
 - Includes timely access to care
 - Who will take care of all these kids?
- Better understanding of attitudes towards screening
- Better understanding of barriers
- Cost studies
- Start the conversation with stakeholders

Patient groups Health care providers Professional healthcare associations General public Payors Industry (diagnostics and therapeutics) Policy makers Government agencies



Acknowledgements

ASK team

Marian Rewers, P.I. Cristy Geno Rasmussen Kim Bautista Judy Baxter Fran Dong Daniel Felipe-Morales Brigitte Frohnert Tricia Gesualdo Michelle Hoffman Xiaofan Jia Rachel Karban

Maricela Munoz Holly O'Donnell Meghan Pauley Flor Sepulveda Crystal Silva Kimber Simmons Andrea Steck Iman Taki Kathy Waugh Joey Wong Liping Yu

> reenwood Dediatrics

Children's Hospital Colorado

Edwin Liu, Marisa Stahl Mary Shull, Pooja Mehta, Ed Hoffenberg, Monique Germone, Sadie Nagle, Erin Sandene, Kevin Carney, Amy Lewis, Chrisann Karr, Sondra Valdez, Chris Martin, Alison Brent

Brett McQueen Rick Bacher David Roth Laura Pyle Jill Norris

And also the thousands of children and their families participating as "Junior Scientists" in these long-term birth cohort and screening studies

The DAISY and the TEDDY Study Groups

- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Child Health and Human Development (NICHD)
- National Institute of Environmental Health Sciences (NIEHS)
- Juvenile Diabetes Research Foundation (JDRF)
- Centers for Disease Control and Prevention (CDC)

DENVER

est. 1860











PEDIATRICS 5280, PC



